论文部分内容阅读
目的 :评价国产重组人生长激素 (Met rhGH)治疗特发性生长激素缺乏症 (IGHD)的疗效和安全性。方法 :对 6 3例IGHD以Met rhGH进行治疗 ,每晚临睡前皮下注射 0 .12IU/ (kg·d)共 6个月。结果 :6 3例患者身高平均增加 ( 6 .8± 1.7)cm ,年生长速度由治疗前的 ( 2 .5± 1.1)cm/年增加到 ( 11.6± 3.3)cm/年 ,身高标准差计分 (SDS)由治疗前的 ( - 4.6± 1.5 )变为 ( - 3 .8± 1.6 ) ;但体重和骨龄无明显变化。治疗前后共有 38.1%的患者出现亚临床甲状腺功能低减 ,30 .9%的患者于注射局部出现短暂的红肿或痒等 ,93 .7%的患者血清出现低滴度的抗rhGH抗体 ,但所有这些现象均未影响患者体格的线性增长。结论 :国产Met rhGH是治疗IGHD的安全、有效的药物
Objective: To evaluate the efficacy and safety of domestic recombinant human growth hormone (rhGH) in the treatment of idiopathic growth hormone deficiency (IGHD). Methods: Sixty-three IGHD patients were treated with Met rhGH, and were subcutaneously injected with 0.12 IU / (kg · d) for 6 months before going to sleep every night. Results: The average height of 6 3 patients was (6.8 ± 1.7) cm. The annual growth rate increased from (2.5 ± 1.1) cm / year to (11.6 ± 3.3) cm / The score (SDS) was changed from (- 4.6 ± 1.5) before treatment to (-3.8 ± 1.6), but there was no significant change in body weight and bone age. Subclinical hypothyroidism occurred in 38.1% of patients before and after treatment, transient redness or itching in 30.9% of the patients, and low serum anti-rhGH antibody in 93.7% None of these phenomena affected the patient’s linear body growth. Conclusion: Domestic rhGH is a safe and effective drug for the treatment of IGHD